Abstract
The study by Yang et al presents a comprehensive investigation into the therapeutic potential of curcumin for gastric cancer (GC). Using network pharmacology, the researchers identified 48 curcumin-related genes, 31 of which overlap with GC targets. Key genes, including ESR1, EGFR, CYP3A4, MAPK14, CYP1A2, and CYP2B6, are linked to poor survival in GC patients. Molecular docking confirmed strong binding affinity of curcumin to these genes. In vitro experiments demonstrated that curcumin effectively inhibits the growth and proliferation of BGC-823, suggesting its therapeutic potential in GC through multiple targets and pathways.